Finally, we show that the ERα/14-3-3 PPI can be stabilized by the natural product FC-A and that this PPI stabilization can be achieved independently from ERα ligand binding in both wild-type ERα and the ERα-Y537S mutant, thus presenting a potential orthogonal therapeutic strategy for targeting endocrine resistance in breast cancer. Here, ESR1 is linked to breast cancer.